On September 24, 3SBIO fell 5.06% in regular trading, trading at 16.11 HKD/share, with turnover of approximately HKD 152 million.

The decline came as the broader biotechnology sector faced significant selling pressure. Within the sector, INNOVENT BIO fell 3.67%, AKESO dropped 4.1%, INNOCARE plunged 11.3%, BEONE MEDICINES slid 1.92%, and REMEGEN declined 8.19%, reflecting a broad-based downturn across the industry.

The pullback follows a sharp rally on September 21, when 3SBIO surged 9.33% to HKD 17.22 on heavy volume of HKD 569 million, driven by sustained share buybacks, insider purchases by Chairman Lou Jing, and institutional accumulation by BlackRock. With the stock having risen substantially from its 52-week low of HKD 14.81, short-term profit-taking pressure intensified. The approaching Mid-Autumn and National Day holiday period further weighed on market sentiment, as investors moved to de-risk positions ahead of the extended break.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)